Home › Funds › Venrock Adviser, LLC › JBIO
Venrock Adviser, LLC position in JBIO
JADE BIOSCIENCES INC · Health Care
Venrock Adviser, LLC reported holding 3,220,364 shares of JBIO (JADE BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$45.2M, representing 2.20% of its reported portfolio and ranking #13 among its reported holdings. Venrock Adviser, LLC has disclosed JBIO holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Venrock Adviser, LLC's JBIO position evolved
Venrock Adviser, LLC first disclosed a stake in JBIO in Q2 2025 at 3,220,364 shares (US$32.2M). The position peaked in Q2 2026 at 3,220,364 shares, worth US$71.6M. Across 6 filings, Venrock Adviser, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 3,220,364 shares valued at US$45.2M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 3.22M | $32.17M | New |
| Q3 2025 | 3.22M | $27.79M | Hold |
| Q4 2025 | 3.22M | $49.69M | Hold |
| Q1 2026 | 3.22M | $45.25M | Hold |
| Q2 2026 | 3.22M | $71.56M | Hold |
| Q3 2026 | 3.22M | $45.25M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About JBIO and 13F data
JBIO (JADE BIOSCIENCES INC) is a Health Care company. 81 other funds we track also report a position in JBIO — the largest reported positions include Paradigm Biocapital Advisors LP (US$85.0M), Fairmount Funds Management LLC (US$64.0M), Bellevue Group AG (US$60.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding JBIO
- Paradigm Biocapital Advisors LP 6.05M sh · $85.05M · Q3 2026
- Fairmount Funds Management LLC 4.55M sh · $63.98M · Q3 2026
- Bellevue Group AG 4.29M sh · $60.33M · Q3 2026
- Avidity Partners Management LP 2.00M sh · $28.10M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 1.84M sh · $25.79M · Q3 2026
- Remedium Capital Partners, LLC 1.81M sh · $25.40M · Q3 2026
- BAKER BROS. ADVISORS LP 1.23M sh · $17.29M · Q3 2026
- Soleus Capital Management, L.P. 1.17M sh · $16.45M · Q3 2026
- Versant Venture Management, LLC 991.78K sh · $13.93M · Q3 2026
- ACORN CAPITAL ADVISORS, LLC 986.76K sh · $13.86M · Q3 2026
- Foresite Capital Management VI LLC 886.67K sh · $12.46M · Q3 2026
- Affinity Asset Advisors, LLC 760.35K sh · $10.68M · Q3 2026
More on Venrock Adviser, LLC
FAQ
How long has Venrock Adviser, LLC held JBIO?
Venrock Adviser, LLC has disclosed JBIO holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
What is Venrock Adviser, LLC's current position in JBIO?
As of Q3 2026, Venrock Adviser, LLC holds 3.22M shares of JBIO (JADE BIOSCIENCES INC), valued at $45.25M, representing 2.20% of its reported portfolio and ranking #13.
Has Venrock Adviser, LLC been buying or selling JBIO?
In the latest 13F filing (Q3 2026), Venrock Adviser, LLC held unchanged its position in JBIO. The position peaked in Q2 2026 at 3.22M shares.
Which other funds hold JBIO?
Other major institutional holders of JBIO include Paradigm Biocapital Advisors LP, Fairmount Funds Management LLC, Bellevue Group AG, among 81 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.